Trust Co. of Vermont boosted its stake in shares of Stryker Co. (NYSE:SYK) by 0.2% in the first quarter, according to its most recent disclosure with the SEC. The firm owned 25,219 shares of the medical technology company’s stock after acquiring an additional 50 shares during the period. Trust Co. of Vermont’s holdings in Stryker were worth $6,143,000 at the end of the most recent quarter.
Other large investors also recently bought and sold shares of the company. Norges Bank purchased a new stake in shares of Stryker during the fourth quarter worth $811,698,000. FMR LLC grew its holdings in shares of Stryker by 246.1% during the fourth quarter. FMR LLC now owns 4,189,778 shares of the medical technology company’s stock worth $1,026,663,000 after buying an additional 2,979,131 shares in the last quarter. FIL Ltd grew its holdings in shares of Stryker by 98.9% during the fourth quarter. FIL Ltd now owns 832,585 shares of the medical technology company’s stock worth $204,017,000 after buying an additional 413,950 shares in the last quarter. Price T Rowe Associates Inc. MD grew its holdings in shares of Stryker by 1.2% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 29,889,733 shares of the medical technology company’s stock worth $7,318,132,000 after buying an additional 364,668 shares in the last quarter. Finally, Fundsmith LLP grew its holdings in shares of Stryker by 5.7% during the fourth quarter. Fundsmith LLP now owns 6,634,893 shares of the medical technology company’s stock worth $1,625,814,000 after buying an additional 357,755 shares in the last quarter. Institutional investors own 71.46% of the company’s stock.
Shares of SYK stock traded down $1.21 during trading on Monday, reaching $255.92. The company’s stock had a trading volume of 7,844 shares, compared to its average volume of 1,218,358. The company has a debt-to-equity ratio of 0.92, a current ratio of 2.89 and a quick ratio of 2.15. The company has a market capitalization of $96.31 billion, a price-to-earnings ratio of 55.78, a P/E/G ratio of 2.79 and a beta of 0.87. The stock’s 50-day moving average price is $241.95 and its 200 day moving average price is $234.17. Stryker Co. has a 1-year low of $171.75 and a 1-year high of $260.00.
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, April 30th. Investors of record on Wednesday, March 31st will be issued a $0.63 dividend. This represents a $2.52 dividend on an annualized basis and a dividend yield of 0.98%. The ex-dividend date of this dividend is Tuesday, March 30th. Stryker’s dividend payout ratio (DPR) is currently 30.51%.
In other Stryker news, CFO Glenn S. Boehnlein sold 2,000 shares of the business’s stock in a transaction that occurred on Monday, March 1st. The shares were sold at an average price of $246.01, for a total transaction of $492,020.00. Following the completion of the transaction, the chief financial officer now owns 12,321 shares in the company, valued at approximately $3,031,089.21. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, VP M Kathryn Fink sold 4,000 shares of the business’s stock in a transaction that occurred on Thursday, April 8th. The stock was sold at an average price of $250.00, for a total transaction of $1,000,000.00. The disclosure for this sale can be found here. Insiders own 6.80% of the company’s stock.
A number of equities research analysts have recently issued reports on the stock. Raymond James upped their target price on shares of Stryker from $240.00 to $255.00 and gave the stock an “outperform” rating in a report on Thursday, January 28th. Truist upped their price objective on shares of Stryker from $210.00 to $245.00 in a report on Wednesday, January 6th. Morgan Stanley dropped their price objective on shares of Stryker from $272.00 to $265.00 and set an “overweight” rating for the company in a report on Thursday, January 28th. BTIG Research upped their price objective on shares of Stryker from $234.00 to $252.00 and gave the company a “buy” rating in a report on Thursday, December 31st. Finally, JPMorgan Chase & Co. upped their price objective on shares of Stryker from $245.00 to $265.00 and gave the company an “overweight” rating in a report on Tuesday, March 2nd. One research analyst has rated the stock with a sell rating, six have given a hold rating, fourteen have issued a buy rating and one has assigned a strong buy rating to the company. The stock presently has an average rating of “Buy” and an average target price of $236.27.
Stryker Company Profile
Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical device products that are used in various medical specialties.
See Also: What is a balanced fund?
Want to see what other hedge funds are holding SYK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stryker Co. (NYSE:SYK).
Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.